Epigenetic suppression of the TGF-beta pathway revealed by transcriptome profiling in ovarian cancer

Genome Research

Volumn 21, Issue 1, 2011, Pages 74-82

  Matsumura, Noriomi ^a,b   Huang, Zhiqing ^a   Mori, Seiichi ^a,d   Baba, Tsukasa ^a,b   Fujii, Shingo ^c   Konishi, Ikuo ^b   Iversen, Edwin S ^a   Berchuck, Andrew ^a   Murphy, Susan K ^a  

^a DUKE UNIVERSITY   (United States)

^b KYOTO UNIVERSITY   (Japan)

^c NATIONAL HOSPITAL ORGANIZATION KYOTO MEDICAL CENTER   (Japan)

^d NATIONAL UNIVERSITY OF SINGAPORE   (Singapore)

Author keywords

[No Author keywords available]

Indexed keywords

DNA METHYLTRANSFERASE INHIBITOR; TRANSCRIPTOME; TRANSFORMING GROWTH FACTOR BETA;

AGE; ARTICLE; CANCER CELL CULTURE; CARCINOGENESIS; CONTROLLED STUDY; DNA METHYLATION; DNA MODIFICATION; GENE ACTIVITY; GENE CLUSTER; GENE EXPRESSION PROFILING; GENE REPRESSION; HUMAN; HUMAN CELL; MICROARRAY ANALYSIS; OVARY CANCER; PRIORITY JOURNAL; SIGNAL TRANSDUCTION;

CELL LINE, TUMOR; DNA METHYLATION; EPIGENESIS, GENETIC; EPIGENOMICS; FEMALE; GENE EXPRESSION PROFILING; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; NEOPLASMS, GLANDULAR AND EPITHELIAL; OLIGONUCLEOTIDE ARRAY SEQUENCE ANALYSIS; OVARIAN NEOPLASMS; SIGNAL TRANSDUCTION; TRANSFORMING GROWTH FACTOR BETA; TUMOR CELLS, CULTURED;

EID: 78651515618     PISSN: 10889051     EISSN: 15495469     Source Type: Journal    
DOI: 10.1101/gr.108803.110     Document Type: Article

References (58)

1. Ahuja N, Li Q, Mohan AL, Baylin SB, Issa JP. 1998. Aging and DNA methylation in colorectal mucosa and cancer. Cancer Res 58: 5489-5494.
2. Alvi AJ, Rader JS, Broggini M, Latif F, Maher ER. 2001. Microsatellite instability and mutational analysis of transforming growth factor beta receptor type II gene (TGFBR2) in sporadic ovarian cancer. Mol Pathol 54: 240-243.
3. Andrechek ER, Mori S, Rempel RE, Chang JT, Nevins JR. 2008. Patterns of cell signaling pathway activation that characterize mammary development. Development 135: 2403-2413.
4. Antequera F. 2003. Structure, function and evolution of CpG island promoters. Cell Mol Life Sci 60: 1647-1658.
5. Baba T, Convery PA, Matsumura N, Whitaker RS, Kondoh E, Perry T, Huang Z, Bentley RC,Mori S, Fujii S, et al. 2009. Epigenetic regulation of CD133 and tumorigenicity of CD133+ ovarian cancer cells. Oncogene 28: 209-218.
6. Badgwell D, Bast RC Jr. 2007. Early detection of ovarian cancer. Dis Markers 23: 397-410.
7. Barton CA, Hacker NF, Clark SJ, O'Brien PM. 2008. DNA methylation changes in ovarian cancer: implications for early diagnosis, prognosis and treatment. Gynecol Oncol 109: 129-139.
8. Berchuck A, Iversen ES, Lancaster JM, Pittman J, Luo J, Lee P, Murphy S, Dressman HK, Febbo PG, West M, et al. 2005. Patterns of gene expression that characterize long-term survival in advanced stage serous ovarian cancers. Clin Cancer Res 11: 3686-3696.
9. Bild AH, Yao G, Chang JT,Wang Q, Potti A, Chasse D, Joshi MB, Harpole D, Lancaster JM, Berchuck A, et al. 2006. Oncogenic pathway signatures in human cancers as a guide to targeted therapies. Nature 439: 353-357.
10. Cairns P. 2009. 5′-Azacytidine expression arrays. Methods Mol Biol 507: 165-174.
11. Chang JT, Nevins JR. 2006. GATHER: A systems approach to interpreting genomic signatures. Bioinformatics 22: 2926-2933.
12. Chen SJ, Ning H, Ishida W, Sodin-Semrl S, Takagawa S, Mori Y, Varga J. 2006. The early-immediate gene EGR-1 is induced by transforming growth factor-beta and mediates stimulation of collagen gene expression. J Biol Chem 281: 21183-21197.
13. Chen HY, Yu SL, Chen CH, Chang GC, Chen CY, Yuan A, Cheng CL,Wang CH, Terng HJ, Kao SF, et al. 2007. A five-gene signature and clinical outcome in non-small-cell lung cancer. N Engl JMed 356: 11-20.
14. Ding W, Tang Q, Espina V, Liotta LA, Mauger DT, Mulder KM. 2005. A transforming growth factor-beta receptor-interacting protein frequently mutated in human ovarian cancer. Cancer Res 65: 6526-6533.
15. Do TV, Kubba LA, Du H, Sturgis CD, Woodruff TK. 2008. Transforming growth factor-b1, transforming growth factor-b2, and transforming growth factor-b3 enhance ovarian cancer metastatic potential by inducing a Smad3-dependent epithelial-to-mesenchymal transition. Mol Cancer Res 6: 695-705.
16. Dunfield LD, Dwyer EJ, Nachtigal MW. 2002. TGF beta-induced Smad signaling remains intact in primary human ovarian cancer cells. Endocrinology 143: 1174-1181.
17. Esteller M. 2007. Cancer epigenomics: DNA methylomes and histone-modification maps. Nat Rev Genet 8: 286-298.
18. Francis-Thickpenny KM, Richardson DM, van Ee CC, Love DR,Winship IM, Baguley BC, Chenevix-Trench G, Shelling AN. 2001. Analysis of the TGF beta functional pathway in epithelial ovarian carcinoma. Br J Cancer 85: 687-691.
19. Furuta J, Nobeyama Y, Umebayashi Y, Otsuka F, Kikuchi K, Ushijima T. 2006. Silencing of Peroxiredoxin 2 and aberrant methylation of 33 CpG islands in putative promoter regions in human malignant melanomas. Cancer Res 66: 6080-6086.
20. Goh L, Murphy SK, Muhkerjee S, Furey TS. 2007. Genomic sweeping for hypermethylated genes. Bioinformatics 23: 281-288.
21. Havrilesky LJ, Hurteau JA, Whitaker RS, Elbendary A, Wu S, Rodriguez GC, Bast RC Jr, Berchuck A. 1995. Regulation of apoptosis in normal and malignant ovarian epithelial cells by transforming growth factor beta. Cancer Res 55: 944-948.
22. Herfs M, Hubert P, Kholod N, Caberg JH, Gilles C, Berx G, Savagner P, Boniver J, Delvenne P. 2008. Transforming growth factor-β1-mediated Slug and Snail transcription factor up-regulation reduces the density of Langerhans cells in epithelial metaplasia by affecting E-cadherin expression. Am J Pathol 172: 1391-1402.
23. Hirashima Y, Kobayashi H, Suzuki M, Tanaka Y, Kanayama N, Terao T. 2003. Transforming growth factor-beta1 produced by ovarian cancer cell line HRA stimulates attachment and invasion through an up-regulation of plasminogen activator inhibitor type-1 in human peritoneal mesothelial cells. J Biol Chem 278: 26793-26802.
24. Hoque MO, Kim MS, Ostrow KL, Liu J, Wisman GB, Park HL, Poeta ML, Jeronimo C, Henrique R, Lendvai A, et al. 2008. Genome-wide promoter analysis uncovers portions of the cancer methylome. Cancer Res 68: 2661-2670.
25. Huang Z,Wen Y, Shandilya R, Marks JR, Berchuck A, Murphy SK. 2006. High throughput detection of M6P/IGF2R intronic hypermethylation and LOH in ovarian cancer. Nucleic Acids Res 34: 555-563.
26. Ibanez de Caceres I, Dulaimi E, Hoffman AM, Al-Saleem T, Uzzo RG, Cairns P. 2006. Identification of novel target genes by an epigenetic reactivation screen of renal cancer. Cancer Res 66: 5021-5028.
27. Ihn H. 2002. Pathogenesis of fibrosis: Role of TGF-beta and CTGF. Curr Opin Rheumatol 14: 681-685.
28. Kang SH, Bang YJ, Im YH, Yang HK, Lee DA, Lee HY, Lee HS, Kim NK, Kim SJ. 1999. Transcriptional repression of the transforming growth factor-beta type I receptor gene by DNA methylation results in the development of TGF-beta resistance in human gastric cancer. Oncogene 18: 7280-7286.
29. Karpf AR, Peterson PW, Rawlins JT, Dalley BK, Yang Q, Albertsen H, Jones DA. 1999. Inhibition of DNA methyltransferase stimulates the expression of signal transducer and activator of transcription 1, 2, and 3 genes in colon tumor cells. Proc Natl Acad Sci 96: 14007-14012.
30. Keen JC, Garrett-Mayer E, Pettit C, Mack KM, Manning J, Herman JG, Davidson NE. 2004. Epigenetic regulation of protein phosphatase 2A (PP2A), lymphotactin (XCL1) and estrogen receptor alpha (ER) expression in human breast cancer cells. Cancer Biol Ther 3: 1304-1312.
31. Kondoh E, Mori S, Yamaguchi K, Baba T, Matsumura N, Cory Barnett J, Whitaker RS, Konishi I, Fujii S, Berchuck A, et al. 2010. Targeting slow-proliferating ovarian cancer cells. Int J Cancer 126: 2448-2456.
32. Kwabi-Addo B, Chung W, Shen L, Ittmann M, Wheeler T, Jelinek J, Issa JP. 2007. Age-related DNA methylation changes in normal human prostate tissues. Clin Cancer Res 13: 3796-3802.
33. Li Q, Ahuja N, Burger PC, Issa JP. 1999. Methylation and silencing of the Thrombospondin-1 promoter in human cancer. Oncogene 18: 3284-3289.
34. Liang G, Gonzales FA, Jones PA, Orntoft TF, Thykjaer T. 2002. Analysis of gene induction in human fibroblasts and bladder cancer cells exposed to the methylation inhibitor 5-aza-29-deoxycytidine. Cancer Res 62: 961-966.
35. Lounis H, Provencher D, Godbout C, Fink D, Milot MJ, Mes-Masson AM. 1994. Primary cultures of normal and tumoral human ovarian epithelium: A powerful tool for basic molecular studies. Exp Cell Res 215: 303-309.
36. Lynch MA, Nakashima R, Song H, DeGroff VL, Wang D, Enomoto T, Weghorst CM. 1998. Mutational analysis of the transforming growth factor beta receptor type II gene in human ovarian carcinoma. Cancer Res 58: 4227-4232.
37. Ma C, Rong Y, Radiloff DR, Datto MB, Centeno B, Bao S, Cheng AW, Lin F, Jiang S, Yeatman TJ, et al. 2008. Extracellular matrix protein betaigh3/TGFBI promotes metastasis of colon cancer by enhancing cell extravasation. Genes Dev 22: 308-321.
38. Massague J. 2008. TGFb in cancer. Cell 134: 215-230.
39. Medici D, Hay ED, Olsen BR. 2008. Snail and Slug promote epithelialmesenchymal transition through beta-catenin-T-cell factor-4-dependent expression of transforming growth factor-beta3. Mol Biol Cell 19: 4875-4887.
40. Mund C, Brueckner B, Lyko F. 2006. Reactivation of epigenetically silenced genes by DNA methyltransferase inhibitors: Basic concepts and clinical applications. Epigenetics 1: 7-13.
41. Muthusamy V, Duraisamy S, Bradbury CM, Hobbs C, Curley DP, Nelson B, Bosenberg M. 2006. Epigenetic silencing of novel tumor suppressors in malignant melanoma. Cancer Res 66: 11187-11193.
42. Nilsson EE, Skinner MK. 2002. Role of transforming growth factor beta in ovarian surface epithelium biology and ovarian cancer. Reprod Biomed Online 5: 254-258.
43. Onwuegbusi BA, Aitchison A, Chin SF, Kranjac T, Mills I, Huang Y, Lao- Sirieix P, Caldas C, Fitzgerald RC. 2006. Impaired transforming growth factor beta signalling in Barrett's carcinogenesis due to frequent SMAD4 inactivation. Gut 55: 764-774.
44. Renzoni EA, Abraham DJ, Howat S, Shi-Wen X, Sestini P, Bou-Gharios G, Wells AU, Veeraraghavan S, Nicholson AG, Denton CP, et al. 2004. Gene expression profiling reveals novel TGFb targets in adult lung fibroblasts. Respir Res 5: 24. doi: 10.1186/1465-9921-5-24.
45. Rodriguez GC, Haisley C, Hurteau J, Moser TL, Whitaker R, Bast RC Jr, Stack MS. 2001. Regulation of invasion of epithelial ovarian cancer by transforming growth factor-beta. Gynecol Oncol 80: 245-253.
46. Shames DS, Girard L, Gao B, Sato M, Lewis CM, Shivapurkar N, Jiang A, Perou CM, Kim YH, Pollack JR, et al. 2006. A genome-wide screen for promoter methylation in lung cancer identifies novel methylation markers for multiple malignancies. PLoS Med 3: e486. doi: 10.1371/journal.pmed.0030486.
47. Suzuki MM, Bird A. 2008. DNA methylation landscapes: Provocative insights from epigenomics. Nat Rev Genet 9: 465-476.
48. Suzuki H, Gabrielson E, Chen W, Anbazhagan R, van Engeland M, Weijenberg MP,Herman JG, Baylin SB. 2002. A genomic screen for genes upregulated by demethylation and histone deacetylase inhibition in human colorectal cancer. Nat Genet 31: 141-149.
49. Tothill RW, Tinker AV, George J, Brown R, Fox SB, Lade S, Johnson DS, Trivett MK, Etemadmoghadam D, Locandro B, et al. 2008. Novel molecular subtypes of serous and endometrioid ovarian cancer linked to clinical outcome. Clin Cancer Res 14: 5198-5208.
50. Ueki T, Walter KM, Skinner H, Jaffee E, Hruban RH, Goggins M. 2002. Aberrant CpG island methylation in cancer cell lines arises in the primary cancers from which they were derived. Oncogene 21: 2114-2117.
51. Umetani N, Mori T, Koyanagi K, Shinozaki M, Kim J, Giuliano AE, Hoon DS. 2005. Aberrant hypermethylation of ID4 gene promoter region increases risk of lymph node metastasis in T1 breast cancer. Oncogene 24: 4721-4727.
52. Ushijima T. 2005. Detection and interpretation of altered methylation patterns in cancer cells. Nat Rev Cancer 5: 223-231. (Pubitemid 40314953)
53. Wen XZ, Akiyama Y, Baylin SB, Yuasa Y. 2006. Frequent epigenetic silencing of the bone morphogenetic protein 2 gene through methylation in gastric carcinomas. Oncogene 25: 2666-2673.
54. West M, Blanchette C, Dressman H, Huang E, Ishida S, Spang R, Zuzan H, Olson JA Jr, Marks JR, Nevins JR. 2001. Predicting the clinical status of human breast cancer by using gene expression profiles. Proc Natl Acad Sci 98: 11462-11467.
55. Yamashita S, Tsujino Y, Moriguchi K, Tatematsu M, Ushijima T. 2006. Chemical genomic screening for methylation-silenced genes in gastric cancer cell lines using 5-aza-29-deoxycytidine treatment and oligonucleotide microarray. Cancer Sci 97: 64-71.
56. Yoo CB, Jones PA. 2006. Epigenetic therapy of cancer: Past, present and future. Nat Rev Drug Discov 5: 37-50.
57. Yu H, Konigshoff M, Jayachandran A, Handley D, Seeger W, Kaminski N, Eickelberg O. 2008. Transgelin is a direct target of TGF-beta/Smad3-dependent epithelial cell migration in lung fibrosis. FASEB J 22: 1778-1789.
58. Zhao H, Shiina H, Greene KL, Li LC, Tanaka Y, Kishi H, Igawa M, Kane CJ, Carroll P, Dahiya R. 2005. CpG methylation at promoter site -140 inactivates TGFbeta2 receptor gene in prostate cancer. Cancer 104: 44-52.